叶颖,方唯一,仇兴标,陈晖,侯旭敏,施鸿毓,戴锦杰,宋洁

• 1:上海交通大学医学院
• 2:上海市胸科医院心内科

摘要(Abstract)：

关键词(KeyWords)：

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 叶颖,方唯一,仇兴标,陈晖,侯旭敏,施鸿毓,戴锦杰,宋洁

参考文献(References)：

• [1]Storrow AB,Gibler WB.Chest pain centers:diagnosis of acute coronary syndromes.Ann Emerg Med,2000,35:449-461.
• [2]Vorchheimer DA,Badimon JJ,Fuster V.Platelet glycoproteinⅡb/Ⅲa receptor antagonists in cardiovascular disease.JAMA,1999,28:1407-1414.
• [3]Kim JH,Jeong MH,Rhew JY.Long-term clinical outcomes of platelet glycoproteinⅡb/Ⅲa inhibitor combined with lowmolec-ular weight heparin in patients with acute coronary syndrome.Circ J,2005,69:159-164.
• [4]Gibson CM,Cannon CP,Daley WL,et al.TIMI frame count:a quantitative method of assessing coronary artery flow.Circula-tion,1996,93:879-888.
• [5]马长生.冠状动脉造影的血流与灌注评价//马长生,主编.冠心病介入治疗——技术与策略.北京:人民卫生出版社,2004:15-16.
• [6]Razakjr OA,Tan HC,Yip WL,et al.Predictors of bleeding complications and thrombocytopenia with the use of abciximab during percutaneous coronary intervention.J Interv Cardiol,2005,18:33-37.
• [7]Bovill EG,Terrin ML,Stump DC,et al.Hemorrhagic events during therapy with recombinant tissue-type plasminogen activa-tor,heparin,and aspirin for acute myocardial infarction.Results of the Thrombolysis in Myocardial Infarction(TIMI),PhaseⅡTrial.Ann Intern Med,1991,115:256-265.
• [8]Valgimigli M,Percoco G,Barbieri D,et al.The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty:the ADVANCE Trial.J Am Coll Cardiol,2004,44:14-19.
• [9]Wyss CA,Roffi M.Platelet inhibition in percutaneous coronary interventions.Herz.,2005,30:189-196.
• [10]Silber S,Albertsson P,Avils FF,et al.Guidelines for percuta-neous coronary interventions.The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology.Eur Heart J,2005,26:804-847.
• [11]Servoss SJ,Wan Y,Snapinn SM,et al.Tirofiban therapy for pa-tients with acute coronary syndromes and prior coronary artery by-pass grafting in the PRISM-PLUS trial.Am J Cardiol,2004,93:843-847.
• [12]A comparison of aspirin plus tirofiban with aspirin plus heparinfor unstable angina.Platelet Receptor Inhibition in Ischemic Syn-drome Management(PRISM)Study Investigators.N Engl J Med,1998,21,338:1498-1505.
• [13]Inhibition of the platelet glycoproteinⅡb/Ⅲa receptor with tiro-fiban in unstable angina and non-Q-wave myocardial infarction.Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms(PRISM-PLUS)Study Investigators.N Engl J Med,1998,338:1488-1497.
• [14]Effects of platelet glycoproteinⅡb/Ⅲa blockade with tirofiban on adverse cardiac events in patients with unstable angina or a-cute myocardial infarction undergoing coronary angioplasty.The RESTORE Investigators.Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.Circulation,1997,96:1445-1453.
• [15]Valgimigli M,Percoco G,Barbieri D,et al,The additive value of tirofiban administered with the high-dose bolus in the preven-tion of ischemic complications during high-risk coronary angio-plasty:the ADVANCE Trial.J Am Coll Cardiol,2004,44:14-19.
• [16]Yang TY,Chang ST,Chung CM,et al.Restoration of normal coronary flowwith tirofiban by intracoronary administration for no-reflow phenomenon after stent deployment.Int Heart J,2005,46:139-145.
• [17]Van't Hof AW,Ernst N,de Boer MJ,et al.Facilitation of pri-mary coronary angioplasty by early start of a glycoprotein2b/3a inhibitor:results of the ongoing tirofiban in myocardial infarction evaluation(On-TIME)trial.Eur Heart J,2004,25:837-846.
• [18]唐强,霍勇,陈明,等.盐酸替罗非班对急性心肌梗死急诊经皮冠状动脉介入治疗中TIMI血流影响的临床研究.中国介入心脏病学杂志,2006,14:97-99.
• [19]侯玉清,周忠江,黎建勇,等.国产替罗非班治疗急性冠状动脉综合征的临床研究.中国介入心脏病学杂志,2007,15:34-36.
• [20]沈杰,张奇,张瑞岩,等.急性ST段抬高型心肌梗死急诊介入治疗前应用替罗非班对疗效的影响.中国介入心脏病学杂志,2008,16:192-196.
• [21]Karvouni E,Katritsis DG,Ioannidis JP.Intravenous glycoproteinⅡb/Ⅲa receptor antagonists reduce mortality after percutaneous coronary interventions.J Am Coll Cardiol,2003,41:26-32.
• [22]Bolognese L,Falsini G,Liistro F,et al.Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous cor-onary interventions:the EVEREST trial.J Am Coll Cardiol,2006,47:522-528.
• [23]Eikelboom JW,Mehta SR,Anand SS,et al.Adverse impact of bleeding on prognosis in patients with acute coronary syndromes.Circulation,2006,114:774-782.
• [24]Boersma E,Harrington RA,Moliterno DJ,et al.Platelet glyco-proteinⅡb/Ⅲa inhibitors in acute coronary syndromes:a meta-analysis of all major randomised clinical trials.Lancet,2002,359:189-198.
• [25]Kunichika H,Ben-Yehuda O,Lafitte S,et al.Effects of glyco-proteinⅡb/Ⅲa inhibition on microvascular flow after coronary reperfusion.A quantitative myocardial contrast echocardiography study.J Am Coll Cardiol,2004,43:276-283.